Generally speaking, you are always in control of the shares you buy in Enzyme products and can redeem them at any time. Occasionally however, some edge cases arise because of the way that some DeFi protocols work. For example, Synthetix typically uses a delayed settlement time of 180 seconds. Further complicating matters, this settlement time is an adjustable parameter by Synthetix governance. In the scenario that a subscriber tries to redeem shares from an Enzyme product that's just made a trade on Synthetix but before that trade has settled, they will not be able to.
If guaranteed 24/7 redeemability is a condition required for you to invest into a product, you should check the product configurations on the product's page to make sure that Synthetix is on the adapter blacklist (ie. Portfolio Manager can never trade on Synthetix). It is important to check that this condition still holds at the time when any upgrade is signaled by a Portfolio Manager.
In an extreme edge case, a Portfolio Manager might be trading Synthetix heavily in which case you will might not have the chance to redeem as often as they would like. If this concerns you, you should look to invest in products which have a Guaranteed Redemption policy. More information can be found on this policy in the Redemptions section. Note that it is your responsibility to check this policy still holds during an upgrade period.
Enzyme is constantly adding new features and integrations with external decentralised finance protocols. Occasionally, these features will require a new release of the core Enzyme contracts. Investors should be aware that at every new Enzyme release, Portfolio Managers can opt in to upgrade their product from the previous version to the new version. This process gives Portfolio Managers an opportunity to change their original product configurations (eg. fees, rule-sets, etc). Once the product configurations are updated and the Portfolio Manager has signaled their intent to migrate to the new Enzyme version, the Portfolio Manager is restricted from accessing the upgrade for 48 hours. This time period gives investors an opportunity to opt out of the product by redeeming their shares.
In order to make this monitoring of events more user friendly, we will be releasing notification services for users in the coming months. In the meantime, any Enzyme upgrades will be well-publicised here, here, and here.
Enzyme takes security very seriously. Any publicly-available Enzyme code has been thoroughly audited; the results are available for anyone to read here. However, when interacting with any smart contract protocol, there is always some degree of risk that an edge case or code vulnerability can result in funds being lost. Investing funds into an Enzyme product is an acknowledgement and acceptance of this risk.
For any questions about these risks, our team is always happy to help.
Enzyme relies on oracles to calculate the GAVs of any investment product. If these oracles are compromised in any way, they can provide attack vectors to users which could lead to a loss of funds.
It is the Portfolio Manager to stay on top of any nuances surrounding tokens. The available asset universe is not intended to be any list of endorsement. Things to look out for could include the risk of token migrations, deviations from the ERC-20 standard, the degree of centralised custodial risk (eg. USDT) and how prices are derived (for example, we use the BTC/ETH rate for WBTC).